KRAS G12C mutation and risk of disease recurrence in stage I surgically resected lung adenocarcinoma.
Early stage LUAD
KRAS mutations
Lymphadenectomy
NGS
Journal
Lung cancer (Amsterdam, Netherlands)
ISSN: 1872-8332
Titre abrégé: Lung Cancer
Pays: Ireland
ID NLM: 8800805
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
26
03
2023
revised:
08
05
2023
accepted:
15
05
2023
medline:
14
6
2023
pubmed:
30
5
2023
entrez:
30
5
2023
Statut:
ppublish
Résumé
KRAS G12C mutations are found in about 12-13% of LUAD samples and it is unclear whether they are associated with worse survival outcomes in resected, stage I LUAD. We assessed whether KRAS-G12C mutated tumours had worse DFS when compared to KRAS-nonG12C mutated tumours and to KRAS wild-type tumours in a cohort of resected, stage I LUAD (IRE cohort). We then leveraged on publicly available datasets (TCGA-LUAD, MSK-LUAD
Identifiants
pubmed: 37253296
pii: S0169-5002(23)00792-4
doi: 10.1016/j.lungcan.2023.107254
pii:
doi:
Substances chimiques
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
KRAS protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
107254Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.